Related Experiment Video
Updated: May 29, 2026
Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
Up-regulation of SLC26A3 enhances oxaliplatin sensitivity in colorectal cancer
Junyang Wang1, Shaodong Tang2, Min Zhang3
1Department of Gastrointestinal Nutrition and Hernia Surgery, The Second Hospital of Jilin University, No. 4026, Yatai Street, Nanguan District, Changchun, 130022, China.
Abstract:
The role of SLC26A3 in the sensitivity to oxaliplatin, a widely used chemotherapy drug for colorectal cancer (CRC), remains unclear. This study aimed to explore the association between SLC26A3 expression and oxaliplatin sensitivity. Total 240 differentially expressed mRNAs were identified, with 124 downregulated and 116 upregulated in oxaliplatin-resistant CRC. WGCNA identified a module significantly associated with resistance. GO and KEGG analyses revealed enrichment in fatty acid metabolic processes and organic anion transmembrane transporter activity. PCA and feature gene selection identified a 15-gene signature, with SLC26A3 highlighted by machine learning models as a key discriminator of chemosensitivity. Immunohistochemical staining and survival analysis indicated that higher SLC26A3 expression correlated with better survival outcomes. Additionally, a significant negative correlation between SLC26A3 and AKT1 was observed, suggesting that while SLC26A3 may enhance oxaliplatin sensitivity, its effect may be overshadowed by other factors in resistant cells. SLC26A3 may play a crucial role in oxaliplatin sensitivity in CRC. The identified gene signature could potentially serve as a biomarker for predicting chemosensitivity to oxaliplatin.
Insights
This study reveals that higher SLC26A3 expression in colorectal cancer (CRC) correlates with better sensitivity to oxaliplatin chemotherapy. A 15-gene signature, including SLC26A3, may predict patient response to this vital cancer treatment.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Oxaliplatin is a key chemotherapy for colorectal cancer (CRC).
- The precise role of SLC26A3 in oxaliplatin sensitivity in CRC is not well understood.
- Identifying biomarkers for chemosensitivity is crucial for personalized CRC treatment.
Purpose of the Study:
- To investigate the association between SLC26A3 expression and oxaliplatin sensitivity in colorectal cancer.
- To identify potential gene signatures that predict response to oxaliplatin therapy.
- To explore the molecular mechanisms underlying SLC26A3's role in CRC chemosensitivity.
Main Methods:
- Differential gene expression analysis of 240 mRNAs in oxaliplatin-resistant CRC.
- Weighted Gene Correlation Network Analysis (WGCNA) to identify relevant gene modules.
- Gene Ontology (GO) and KEGG pathway analyses.
- Principal Component Analysis (PCA) and machine learning for feature gene selection.
- Immunohistochemistry and survival analysis.
Main Results:
- A 15-gene signature was identified, with SLC26A3 highlighted as a key predictor of chemosensitivity.
- Higher SLC26A3 expression was significantly correlated with better patient survival outcomes.
- A negative correlation between SLC26A3 and AKT1 suggests complex regulatory interactions.
- Enrichment analysis pointed to fatty acid metabolism and organic anion transport.
Conclusions:
- SLC26A3 plays a significant role in determining oxaliplatin sensitivity in colorectal cancer.
- The identified 15-gene signature, featuring SLC26A3, shows promise as a predictive biomarker for oxaliplatin chemosensitivity.
- Further research into the SLC26A3-AKT1 interaction may elucidate resistance mechanisms.
Related Concept Videos
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase